Psychedelics for easing existential distress in terminally ill patients

14 clinical studies have explored the use of psychedelics and ketamine for existential distress in terminally ill patients.

• Existential distress in terminal illness is linked to anxiety and depression.
• Psychotherapeutic interventions show short-lived effectiveness, with no proven pharmacological options.
• Early studies from 1960 to 1980 and more recent studies with classic psychedelics and ketamine indicate promising results despite methodological flaws.
• Positive effects on existential and spiritual well-being, quality of life, and symptoms of anxiety and depression are reported.
• Mystical experiences during treatment may correlate with better outcomes.
• Few adverse effects have been noted, but larger, more diverse studies are necessary for stronger conclusions.

Simplified